Tranche Update on REYON Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on July 6, 2018.
October 10, 2018 at 04:00 am EDT
Share
From July 6, 2018 to September 30, 2018, the company has repurchased 235,340 shares, representing 1.4% for KRW 4,870.29 million. With this, the company has completed the repurchase of 235,340 shares, representing 1.4% for KRW 4,870.29 million under the buyback announced on July 6, 2018.
REYON PHARMACEUTICAL Co. Ltd. is a Korea-based company engaged in the provision of pharmaceutical products. The Companyâs products consist of remedies for circulatory systems, endocrine systems, digestive systems, respiratory systems, urinary systems and nervous systems, as well as eye drops, antibiotics, fever reducers, painkillers, anti-inflammatory drugs, antihistaminic agents, enzyme preparations, arthritis remedies, antitumor drugs and topical anesthetics, among others. It also produces pharmaceutical raw materials, such as arbekacin sulfate, alibendol, carvedilol, enocitabine, gemcitabine, glimepiride, lamotrigine, meloxicam, oxaliplatin, pioglitazone hydrochloride, ramipril, streptokinase, tacrolimus, thioctic acid, teicoplanin, voglibose and others.
REYON PHARMACEUTICAL CO., LTD. 
